852626-89-2
Chemical Structure
Samidorphan
Synonym(s): ALKS-33; RDC-0313
- CAS No.: 852626-89-2
- Formula:C21H26N2O4
- Molecular Weight:370.44
IUPAC Name: (4bR,8aS,9R)-11-(cyclopropylmethyl)-4,8a-dihydroxy-6-oxo-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthrene-3-carboxamide
InChIKey: RYIDHLJADOKWFM-MAODMQOUSA-N
SMILES: O=C(N)C1=CC=C(C[C@H]([C@@]2(CC3)O)N(CC4)CC5CC5)C([C@]42CC3=O)=C1O
Biological Activity: Samidorphan (ALKS-33) is an orally active opioid receptor modulator that targets μ-opioid, κ-opioid, and δ-opioid receptors. Samidorphan acts as a μ-opioid receptor antagonist and a partial agonist at κ-opioid and δ-opioid receptors. In vivo, Samidorphan functions primarily as an opioid receptor antagonist and ameliorates depressive behaviors in animals[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Samidorphan | 99.83% | Samidorphan (ALKS-33) is an orally active opioid receptor modulator that targets μ-opioid, κ-opioid, and δ-opioid receptors. Samidorphan acts as a μ-opioid receptor antagonist and a partial agonist at κ-opioid and δ-opioid receptors. In vivo, Samidorphan functions primarily as an opioid receptor antagonist and ameliorates depressive behaviors in animals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Samidorphan (Standard) | ≥98% | Samidorphan (Standard) is the analytical standard of Samidorphan. This product is intended for research and analytical applications. Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo. Samidorphan can improve the behavior of depressed animals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Samidorphan-d4 | Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Samidorphan-d5 | Samidorphan-d5 (ALKS-33-d5) is is a deuterated compound of Samidorphan. Samidorphan is an orally active opioid system modulator that binds with high affinity to μ-opioid, κ-opioid, and δ-opioid receptors. Samidorphan is a μ-opioid receptor antagonist and a partial agonist at k-opioid and δ-opioid receptors. Samidorphan acts primarily as an opioid receptor antagonist in vivo. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. McElroy SL, et al. A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord. 2013 Apr;46(3):239-45. [Content Brief]
- [2]. Rehan ST, et al. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. Ann Med Surg (Lond). 2022 Jun 30;79:104115. [Content Brief]
- [3]. Mark S. Todtenkopf, et al. Buprenorphine in Combination with Samidorphan (ALKS 33) Results in Antidepressive-Like Effects in Two Distinct Rat Models. Eur Neuropsychopharmacol. 2014;24aSuppl 2):S366.
- [4]. Shravni V, et al. Comparative Effects of Buprenorphine and Samidorphan on Locomotor Behavior in vivo. Scientific Research Journal of Pharmacy 2021, Volume 1,Issue: 1 (June-July).
- [5]. Smith KL, et al. Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat. Neuropharmacology. 2019 Mar 1;146:316-326. [Content Brief]
